A European survey indicates that VT management generally aligns with guidelines, with frequent use of antiarrhythmic drugs and ICDs for high-risk patients, but relatively low rates of catheter ablation.
Supports guideline-concordant VT management in Europe; leaves open reasons for low ablation rates and need for prospective outcome data.
The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in the management of ventricular tachycardia (VT). The data are based on an electronic questionnaire sent to the members of the EHRA Research Network. Responses were received from 31 centres in 16 countries. The results of the survey show that the management of VT is in general in accordance with guidelines. Antiarrhythmic drugs are still frequently used for VT treatment. In patients at high risk of sudden cardiac death, an implantable cardioverter-defibrillator is routinely recommended, while the treatment options vary for patients with moderate or low risk. A discreet attitude is adopted for catheter ablation in high-risk patients as demonstrated by a relatively low rate of catheter ablation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2015) studied this question.